Abstract
Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation: After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines. Funding: Bill & Melinda Gates Foundation.
Original language | English |
---|---|
Pages (from-to) | 503-521 |
Number of pages | 19 |
Journal | Lancet |
Volume | 398 |
Issue number | 10299 |
DOIs | |
Publication status | Published - 7 Aug 2021 |
Fingerprint
Dive into the research topics of 'Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Lancet, Vol. 398, No. 10299, 07.08.2021, p. 503-521.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019
T2 - a systematic analysis for the Global Burden of Disease Study 2020, Release 1
AU - GBD 2020, Release 1, Vaccine Coverage Collaborators
AU - Galles, Natalie C.
AU - Liu, Patrick Y.
AU - Updike, Rachel L.
AU - Fullman, Nancy
AU - Nguyen, Jason
AU - Rolfe, Sam
AU - Sbarra, Alyssa N.
AU - Schipp, Megan F.
AU - Marks, Ashley
AU - Abady, Gdiom Gebreheat
AU - Abbas, Kaja M.
AU - Abbasi, Sumra Wajid
AU - Abbastabar, Hedayat
AU - Abd-Allah, Foad
AU - Abdoli, Amir
AU - Abolhassani, Hassan
AU - Abosetugn, Akine Eshete
AU - Adabi, Maryam
AU - Adamu, Abdu A.
AU - Adetokunboh, Olatunji O.
AU - Adnani, Qorinah Estiningtyas Sakilah
AU - Advani, Shailesh M.
AU - Afzal, Saira
AU - Aghamir, Seyed Mohammad Kazem
AU - Ahinkorah, Bright Opoku
AU - Ahmad, Sohail
AU - Ahmad, Tauseef
AU - Ahmadi, Sepideh
AU - Ahmed, Haroon
AU - Ahmed, Muktar Beshir
AU - Ahmed Rashid, Tarik
AU - Ahmed Salih, Yusra
AU - Akalu, Yonas
AU - Aklilu, Addis
AU - Akunna, Chisom Joyqueenet
AU - Al Hamad, Hanadi
AU - Alahdab, Fares
AU - Albano, Luciana
AU - Alemayehu, Yosef
AU - Alene, Kefyalew Addis
AU - Al-Eyadhy, Ayman
AU - Alhassan, Robert Kaba
AU - Ali, Liaqat
AU - Aljunid, Syed Mohamed
AU - Almustanyir, Sami
AU - Altirkawi, Khalid A.
AU - Alvis-Guzman, Nelson
AU - Amu, Hubert
AU - Andrei, Catalina Liliana
AU - Fernandes, João C.
AU - Lim, Stephen S.
AU - Mosser, Jonathan F.
N1 - Funding Information: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. We wish to acknowledge the members of the WUENIC Working Group, expressing our gratitude for the invaluable insights and thoughtful discussions that they have shared with us over the course of this work. Olatunji O Adetokunboh acknowledges the support of the South African Department of Science and Innovation, and National Research Foundation, South Africa. Saira Afzal acknowledges support from the Department of Community Medicine, King Edward Medical University, Lahore, Pakistan. Syed Mohamed Aljunid acknowledges the Department of Health Policy and Management, Faculty of Public Health, Kuwait University, Kuwait, and International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia, for the approval and support to participate in this research project. Sonu Bhaskar acknowledges funding support from the NSW Ministry of Health and institutional support from NSW Health Pathology. Till Winfried Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. Felix Carvalho acknowledges UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from Fundação para a Ciência e Tecnologia (FCT)/Ministro da Ciência, Tecnologia e Ensino Superior (MCTES) through national funds. Vera Marisa Costa acknowledges her grant (SFRH/BHD/110001/2015), received by Portuguese national funds through FCT, IP, under the Norma Transitória DL57/2016/CP1334/CT0006. Jan-Walter De Neve acknowledges support from the Alexander von Humboldt Foundation. Mark Rohit Francis acknowledges personal support by the Health Sciences Unit, Faculty of Social Sciences, Tampere University, Finland. Vivek Kumar Gupta acknowledges funding support from the NHMRC Australia. Sheikh Mohammed Shariful Islam acknowledges support by the NHMRC and the National Heart Foundation of Australia. Yun Jin Kim was supported by the Research Management Centre, Xiamen University Malaysia (number XMUMRF/2020-C6/ITCM/0004). Iván Landires is a member of the Sistema Nacional de Investigación, which is supported by the Panama's Secretaría Nacional de Ciencia, Tecnología e Innovación (SENACYT). Lorenzo Giovanni Mantovani acknowledges support from the Italian Ministry of Health - Ricerca Corrente - IRCCS MultiMedica. Philippa C Matthews acknowledges funding support by a Wellcome intermediate fellowship (grant reference number 110110Z/15/Z). Mariam Molokhia is supported by the National Institute for Health Research Biomedical Research Center at Guy's and St Thomas' National Health Service Foundation Trust and King's College London, UK. Jonathan F Mosser acknowledges support from the Bill & Melinda Gates Foundation (OPP1182474). Ulrich Otto Mueller acknowledges funding support by the German National Cohort Study. Jagadish Rao Padubidri acknowledges the Manipal Academy of Higher Education Mangalore for their constant support in research publication. Abdallah M Samy acknowledges support from the Fellowship of the Egyptian Fulbright Mission programme. Alyssa N Sbarra acknowledges support from the Bill & Melinda Gates Foundation (OPP1182474). Charles Shey Wiysonge acknowledges support from the South African Medical Research Council. Funding Information: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city, or area or of its authorities or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The authors alone are responsible for the views expressed in this Article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. We wish to acknowledge the members of the WUENIC Working Group, expressing our gratitude for the invaluable insights and thoughtful discussions that they have shared with us over the course of this work. Olatunji O Adetokunboh acknowledges the support of the South African Department of Science and Innovation, and National Research Foundation, South Africa. Saira Afzal acknowledges support from the Department of Community Medicine, King Edward Medical University, Lahore, Pakistan. Syed Mohamed Aljunid acknowledges the Department of Health Policy and Management, Faculty of Public Health, Kuwait University, Kuwait, and International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia, for the approval and support to participate in this research project. Sonu Bhaskar acknowledges funding support from the NSW Ministry of Health and institutional support from NSW Health Pathology. Till Winfried Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. Felix Carvalho acknowledges UID/MULTI/04378/2019 and UID/QUI/50006/2019 support with funding from Fundação para a Ciência e Tecnologia (FCT)/Ministro da Ciência, Tecnologia e Ensino Superior (MCTES) through national funds. Vera Marisa Costa acknowledges her grant (SFRH/BHD/110001/2015), received by Portuguese national funds through FCT, IP, under the Norma Transitória DL57/2016/CP1334/CT0006. Jan-Walter De Neve acknowledges support from the Alexander von Humboldt Foundation. Mark Rohit Francis acknowledges personal support by the Health Sciences Unit, Faculty of Social Sciences, Tampere University, Finland. Vivek Kumar Gupta acknowledges funding support from the NHMRC Australia. Sheikh Mohammed Shariful Islam acknowledges support by the NHMRC and the National Heart Foundation of Australia. Yun Jin Kim was supported by the Research Management Centre, Xiamen University Malaysia (number XMUMRF/2020-C6/ITCM/0004). Iván Landires is a member of the Sistema Nacional de Investigación, which is supported by the Panama's Secretaría Nacional de Ciencia, Tecnología e Innovación (SENACYT). Lorenzo Giovanni Mantovani acknowledges support from the Italian Ministry of Health - Ricerca Corrente - IRCCS MultiMedica. Philippa C Matthews acknowledges funding support by a Wellcome intermediate fellowship (grant reference number 110110Z/15/Z). Mariam Molokhia is supported by the National Institute for Health Research Biomedical Research Center at Guy's and St Thomas' National Health Service Foundation Trust and King's College London, UK. Jonathan F Mosser acknowledges support from the Bill & Melinda Gates Foundation (OPP1182474). Ulrich Otto Mueller acknowledges funding support by the German National Cohort Study. Jagadish Rao Padubidri acknowledges the Manipal Academy of Higher Education Mangalore for their constant support in research publication. Abdallah M Samy acknowledges support from the Fellowship of the Egyptian Fulbright Mission programme. Alyssa N Sbarra acknowledges support from the Bill & Melinda Gates Foundation (OPP1182474). Charles Shey Wiysonge acknowledges support from the South African Medical Research Council. Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. Publisher Copyright: © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2021/8/7
Y1 - 2021/8/7
N2 - Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation: After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines. Funding: Bill & Melinda Gates Foundation.
AB - Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation: After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines. Funding: Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85110301351&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)00984-3
DO - 10.1016/S0140-6736(21)00984-3
M3 - Article
C2 - 34273291
SN - 0140-6736
VL - 398
SP - 503
EP - 521
JO - Lancet
JF - Lancet
IS - 10299
ER -